Advertisement
NCNA vs PALI
Which Stock Would AI Choose? NuCana (NCNA) vs. Palisade Bio (PALI) Stock Comparison
Key Takeaways
- NCNA (NuCana plc) is a clinical-stage oncology developer whose lead program, NUC-7738, targets PD-1 inhibitor-resistant melanoma, while PALI (Palisade Bio) is a clinical-stage inflammatory bowel disease (IBD) company advancing its PALI-2108 PDE4 inhibitor prodrug.
- PALI carries a materially larger market capitalization and a broad analyst following with a consensus "Strong Buy" rating, whereas NCNA trades as a micro-cap with far thinner institutional coverage.
- Both companies remain pre-revenue and depend on clinical milestones and cash runway, making them data-driven, high-volatility names rather than earnings-driven investments.
- Recent market activity has been negative for both tickers, though NCNA has shown more pronounced drawdowns over the past year relative to PALI's more moderate, choppy decline.
- For additional context, explore NCNA Major News and NCNA Today's Price Move, as well as PALI Major News and PALI Today's Price Move.
- To see how automated strategies are positioning across this kind of market, visit the curated Trending AI Robots page.
Introduction
Investors evaluating speculative biotechnology names often weigh two very different profiles: deep-value, catalyst-heavy micro-caps and better-capitalized developers with visible clinical roadmaps. This stock comparison examines NCNA (NuCana plc), a UK-based oncology company, against PALI (Palisade Bio), a U.S.-based IBD-focused biopharmaceutical firm. Both trade well below their historical highs, remain pre-revenue, and are driven primarily by clinical data and regulatory milestones. Understanding their relative performance and market positioning can help traders and longer-term investors assess where risk, capital, and catalysts currently sit.
NCNA Overview and Recent Performance
NCNA, or NuCana plc, is a clinical-stage biopharmaceutical company headquartered in Edinburgh, UK, focused on transforming widely used chemotherapy agents into more effective medicines through its ProTide technology. Its two lead programs are NUC-7738, an anti-cancer agent advancing in a Phase 2 expansion study in PD-1 inhibitor-resistant melanoma, and NUC-3373, a thymidylate synthase inhibitor in earlier evaluation.
In recent weeks, NuCana has reported progress including FDA (U.S. Food and Drug Administration) clearance of an Investigational New Drug (IND) application for NUC-7738 and a European composition-of-matter patent grant. Management has indicated its cash position is expected to fund operations into 2029. Despite these developments, the stock has traded at micro-cap levels with a market capitalization in the single-digit millions, and its share price has declined sharply over the trailing year. Persistent pre-revenue losses and ongoing cash burn have weighed on sentiment, contributing to a technical posture that several data providers characterize as bearish or "sell."
PALI Overview and Recent Performance
PALI, or Palisade Bio, is a clinical-stage biopharmaceutical company based in Denver, Colorado, developing once-daily oral PDE4 (phosphodiesterase-4) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Its lead candidate, PALI-2108, is being advanced for ulcerative colitis and Crohn's disease, with Phase 2 studies expected to begin in the second half of 2026.
Recent developments include FDA clearance of the IND for PALI-2108, Health Canada approval to proceed with a Phase 2 ulcerative colitis trial, and additional Phase 1b data presentations. Palisade Bio also reported a cash position intended to fund operations through key Phase 2 readouts anticipated in 2027–2028. The stock holds a much larger market capitalization than NCNA and carries a consensus "Strong Buy" rating from multiple covering analysts with price targets well above its current trading range. Nevertheless, PALI's share price has also declined in recent months, reflecting broader pressure on speculative biotech names despite the positive clinical narrative.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page curates a selection of AI trading bots from a broader library of hundreds of automated strategies that collectively trade thousands of different tickers. Because only the most suitable bots for current market conditions earn a place in this featured section, the page serves as a useful reference for identifying strategies aligned with prevailing volatility and trend regimes. The available bots span varied trading styles, timeframes, risk profiles, performance statistics, and sets of tickers, so no single approach fits every investor. Reviewing this curated list can help traders evaluate which automated approaches may complement their own analysis. Explore the Trending AI Robots section to see the strategies currently standing out.
Head-to-Head Comparison
The clearest contrast between these two names is scale and sector focus. NCNA targets oncology, a high-competition field where its micro-cap valuation and relatively thin institutional base amplify sensitivity to any single data readout. PALI operates in gastrointestinal and IBD therapeutics, with a lead program engineered for local delivery and an effort to minimize systemic side effects.
On growth drivers, both rely on clinical catalysts: NuCana's final Phase 2 melanoma data and potential regulatory discussions, versus Palisade's Phase 2 trial initiations and future efficacy readouts. In terms of recent momentum, neither has escaped the sector-wide pullback in speculative biotech, though NuCana's relative performance has been notably weaker over the trailing year. Risk profiles differ in kind: NuCana carries execution and financing risk at a very small capitalization, while Palisade, despite a stronger cash cushion and analyst support, faces binary clinical outcomes and a meaningfully higher short-interest ratio. Market sentiment is comparatively more constructive for PALI given its analyst coverage and institutional ownership trends, while NCNA's sentiment remains more cautious.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor PALI over NCNA in the current environment. Palisade Bio exhibits comparatively more stable positioning through a larger market capitalization, a longer stated cash runway, broader analyst endorsement, and a more defined near-term catalyst path into Phase 2 development. NuCana's oncology pipeline offers meaningful potential upside, but its micro-cap valuation, sharper recent drawdown, and less consistent trend structure suggest higher relative uncertainty. This assessment is probabilistic rather than definitive and reflects current trend consistency, catalyst visibility, and relative market positioning rather than a prediction of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NCNA is a Hold and PALI is a Hold.
NCNA's RSI Indicator ascends from oversold territory
The RSI Indicator for NCNA moved out of oversold territory on October 23, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In 34 of the 36 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for NCNA just turned positive on October 26, 2026. Looking at past instances where NCNA's MACD turned positive, the stock continued to rise in 27 of 37 cases over the following month. The odds of a continued upward trend are 73%.
Following a +2.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where NCNA advanced for three days, in 158 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NCNA as a result. In 86 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NCNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NCNA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.194) is normal, around the industry mean (3.498). P/E Ratio (0.019) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. NCNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NCNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for PALI turns negative, indicating new downward trend
PALI saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In 90 of the 95 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PALI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PALI entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PALI's RSI Indicator exited the oversold zone, 32 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 67 of 72 cases where PALI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for PALI just turned positive on November 04, 2026. Looking at past instances where PALI's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Following a +11.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where PALI advanced for three days, in 168 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PALI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.618) is normal, around the industry mean (3.498). P/E Ratio (1.738) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. PALI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PALI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NCNA | PALI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 2 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 84 | 83 | |
P/E GROWTH RATING 1..100 | 5 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NCNA's Valuation (51) in the Biotechnology industry is in the same range as PALI (76) in the null industry. This means that NCNA’s stock grew similarly to PALI’s over the last 12 months.
NCNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PALI (100) in the null industry. This means that NCNA’s stock grew similarly to PALI’s over the last 12 months.
NCNA's SMR Rating (98) in the Biotechnology industry is in the same range as PALI (98) in the null industry. This means that NCNA’s stock grew similarly to PALI’s over the last 12 months.
PALI's Price Growth Rating (83) in the null industry is in the same range as NCNA (84) in the Biotechnology industry. This means that PALI’s stock grew similarly to NCNA’s over the last 12 months.
NCNA's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for PALI (97) in the null industry. This means that NCNA’s stock grew significantly faster than PALI’s over the last 12 months.
| NCNA | PALI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 73% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 77% | 8 days ago 85% |
| Declines ODDS (%) | 21 days ago 90% | 6 days ago 90% |
| BollingerBands ODDS (%) | N/A | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NCNA’s FA Score shows that 1 FA rating(s) are green while PALI’s FA Score has 0 green FA rating(s).
- NCNA’s FA Score: 1 green, 4 red.
- PALI’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NCNA’s TA Score shows that 4 TA indicator(s) are bullish while PALI’s TA Score has 5 bullish TA indicator(s).
- NCNA’s TA Score: 4 bullish, 3 bearish.
- PALI’s TA Score: 5 bullish, 3 bearish.
Price Growth
NCNA (@Biotechnology) experienced а -6.22% price change this week, while PALI (@Biotechnology) price change was -8.13% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
NCNA is expected to report earnings on Nov 12, 2026.
PALI is expected to report earnings on Mar 31, 2027.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NCNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NCNA has been closely correlated with TAOX. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if NCNA jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To NCNA | 1D Price Change % | ||
|---|---|---|---|---|
| NCNA | 100% | -2.38% | ||
| TAOX - NCNA | 92% Closely correlated | -5.15% | ||
| PALI - NCNA | 81% Closely correlated | -5.04% | ||
| PLX - NCNA | 34% Loosely correlated | +11.28% | ||
| INMB - NCNA | 34% Loosely correlated | -2.65% | ||
| IOVA - NCNA | 34% Loosely correlated | -1.10% | ||
More | ||||
PALI and
Correlation & Price change
A.I.dvisor indicates that over the last year, PALI has been closely correlated with RNAC. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if PALI jumps, then RNAC could also see price increases.
| Ticker / NAME | Correlation To PALI | 1D Price Change % | ||
|---|---|---|---|---|
| PALI | 100% | -5.04% | ||
| RNAC - PALI | 81% Closely correlated | -1.85% | ||
| AGEN - PALI | 81% Closely correlated | -1.82% | ||
| NCNA - PALI | 81% Closely correlated | -2.38% | ||
| TAOX - PALI | 81% Closely correlated | -5.15% | ||
| NRXP - PALI | 74% Closely correlated | -0.84% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ADDS | 25.40 | N/A | N/A |
| Hedgeye Index Adds ETF (ADDS) | |||
| NBOS | 28.21 | -0.03 | -0.11% |
| Neuberger Option Strategy ETF (NBOS) | |||
| SCMB | 25.02 | -0.10 | -0.40% |
| Schwab Municipal Bond ETF (SCMB) | |||
| NEMD | 50.62 | -0.24 | -0.48% |
| Neuberger Emerging Markets Debt Hard Currency ETF (NEMD) | |||
| IBGM | 23.38 | -0.30 | -1.27% |
| iShares iBonds Dec 2056 Term Treasury ETF (IBGM) | |||